MedPath

Personal Patient Profile - Prostate (P3P) II: Effectiveness-Implementation Trial in Diverse Health Care Networks

Not Applicable
Completed
Conditions
Prostate Cancer
Interventions
Behavioral: Personal Patient Profile - Prostate (P3P)
Behavioral: Standard prostate cancer information websites
Registration Number
NCT01844999
Lead Sponsor
Dana-Farber Cancer Institute
Brief Summary

The purpose of this study is to determine whether using the P3P website can increase decisional preparation and satisfaction, and decrease decisional conflict, in men deciding how to manage early stage prostate cancer.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
Male
Target Recruitment
392
Inclusion Criteria
  • Biopsy-proven diagnosis of prostate cancer, T1 or T2 of any risk level
  • Biopsy done at enrolling site
  • Upcoming appointment with consulting specialist at enrolling study site
  • Able to read, write, understand English
Read More
Exclusion Criteria
  • Two or more post-biopsy specialist consults
  • Begun treatment (or active surveillance)
Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Usual patient education + P3P decision support websitePersonal Patient Profile - Prostate (P3P)-
Usual patient education + standard educational websitesStandard prostate cancer information websites-
Primary Outcome Measures
NameTimeMethod
Preparation for decision making1-month after study entry

Graham and O'Connor, 1995, Preparation for decision making scale

Decisional conflictChange from baseline to 6-months

O'Connor, 1995, Decisional conflict scale

Satisfaction with decision6-months after study entry

Holmes-Rovner et al, 1996, Satisfaction with decision scale

Secondary Outcome Measures
NameTimeMethod
Concordance of care choice selected with self-reported influential personal preferences6-months from study entry

Odds ratio of selecting a care option for prostate cancer concordant with avoiding prioritized side effects (XBRT or brachytherapy if concerned with sexual function; prostatectomy if concerned with bowel function; active surveillance if concerned with sexual, bowel, and/or bladder function; any treatment if not concerned with any side effect).

Net cost and benefit of the intervention1-week after study entry

Cost to the patient will be measured in hours valued according to patient work status, income, and use of time. Benefit will be measured with Willingness to pay.

Time to treatment decision6-months from study entry

Duration (in days) from pre-decision baseline questionnaire until patient decides on a care option for prostate cancer, either an active treatment type or active surveillance. Measured by patient recall at 6-months.

Trial Locations

Locations (4)

Kaiser Permanente - Souther California

🇺🇸

Downey, California, United States

Kaiser Permanente - Southern California

🇺🇸

Los Angeles, California, United States

Emory Healthcare

🇺🇸

Atlanta, Georgia, United States

Beth Israel Deaconess Medical Center

🇺🇸

Boston, Massachusetts, United States

© Copyright 2025. All Rights Reserved by MedPath